CardioDX

About CardioDX

CardioDx, Inc. was a molecular diagnostics company founded in 2003 by David Levison, focusing on the development and commercialization of genomic tests for cardiovascular diseases. The firm operated from its headquarters in Redwood City, California, and aimed to improve treatment decisions and patient outcomes while reducing healthcare costs through advanced genomic technologies. Over its 16-year history, the company attracted significant venture capital, raising approximately $297 million from prominent investors including Kleiner Perkins, Intel Capital, and J.P. Morgan.

The company's flagship product was the Corus CAD test, a blood-based gene expression test designed to help clinicians assess the likelihood of obstructive coronary artery disease (CAD) in non-diabetic patients presenting with symptoms like chest pain. The test worked by analyzing the expression levels of 23 specific genes from a simple blood draw, integrating this data with a patient's age and sex to produce a score from 1 to 40. This score quantified the probability of a patient having obstructive CAD, aiming to provide a non-invasive tool to rule out the need for more costly and invasive procedures, such as cardiac catheterization. The business model centered on selling this test, which had a list price of $1,195, directly to healthcare providers and securing reimbursement from insurers.

A significant milestone was achieved when the company secured Medicare coverage for the Corus CAD test, making it accessible to over 40 million eligible patients and boosting its commercial prospects. However, this proved to be a critical dependency. In late 2018, the Medicare contractor rescinded coverage, citing a lack of evidence that the test improved patient outcomes or changed physician management in a beneficial way. This decision was financially crippling for CardioDx, as Medicare was a primary purchaser. Compounding these challenges, the company faced whistleblower complaints from former employees alleging that it had knowingly sold an unnecessary test, defrauding Medicare. In the face of these setbacks, CardioDx attempted an initial public offering in 2013 and 2014 but ultimately withdrew its filing. The loss of Medicare coverage proved insurmountable, leading the company to lay off its 110 employees and cease operations in January 2019, subsequently auctioning off its laboratory equipment.